### Clinical Trials Information #55

**Principal Investigator**
James Markmann, MD, PhD and Michael Rickels, MD

**Study Title:**
A Phase 1/2 Study to Evaluate the Safety, Tolerability, and Efficacy of VX-264 in Subjects With Type 1 Diabetes Mellitus

**Purpose:**
To evaluate the safety and effectiveness of VX-264, a surgically implanted device containing stem cell derived islet cells for the treatment of Type 1 Diabetes.

**Brief Description**
VX-264 is surgically implanted below the muscle in the abdomen. It contains a mixture of cells made from human embryonic stem cells that can make insulin and other hormones like glucagon that are usually made in the pancreatic islets.

**Eligibility**
18-65 years old with Type 1 Diabetes
Hgb A1C 7% to 9.5%
Blood Type A or AB

**Compensation (if applicable)**
Travel and hotel costs will be covered

**Which section would you like the trial listed under?**
Rodeugh Center Trials

**Name**
Mary Kaminski

**Phone**
(215) 662-2037

**Email:**
mary.kaminski@pennmedicine.upenn.edu